Products
Pre-made Sintilimab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-523
Pre-Made Sintilimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease, and has been approved in China.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-523-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Sintilimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody |
| INN Name | Sintilimab |
| Target | PDCD1/PD-1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Adimab;Innovent Biologics;Jiangsu Provincial Peoples Hospital;Sun Yat-Sen University |
| Conditions Approved | Hodgkin's disease |
| Conditions Active | Gastric cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Extranodal NK-T-cell lymphoma;Small cell lung cancer;Solid tumours |
| Conditions Discontinued | na |
| Development Tech | na |
<